Policy Statement 6.30 - Neurotoxins and Dermal Fillers in Dentistry

1. Position Summary

The use of neurotoxins and dermal fillers in dentistry is dependent on the dentist’s clinical judgement in consultation and with the consent of the patient. These procedures must only be carried out by dentists who are appropriately educated. 

2. Background

2.1. The use of neurotoxins and dermal fillers has become part of the practice of dentistry over the past decade.

2.2. Dentists through their oral and maxillofacial anatomy education are the only appropriately qualified dental practitioner to administer neurotoxins and dermal fillers.

2.3. The Board has released communiques on the use of neurotoxins and dermal fillers in dentistry and had released an Interim Policy which has been subsequently withdrawn from its website.

2.4. The Therapeutic Goods Administration (TGA) regulates the use of neurotoxins and dermal fillers.

2.5. Some applications of neurotoxins and dermal fillers are classified as Off-Label Use. The TGA does not assess off-label use.

2.6. Off-Label use of scheduled medication requires clinical judgement of the practitioner and consent of the patient.

2.7. The use of neurotoxins and dermal fillers may be limited by state and territory drugs and poisons legislation.

2.8. There are restrictions on the advertising of neurotoxins and dermal fillers. 


2.9. BOARD is the Dental Board of Australia

2.10. CONTINUING PROFESSIONAL DEVELOPMENT is the means by which members of the profession maintain, improve and broaden their knowledge, expertise and competence, and develop personal and professional qualities required throughout their professional lives.

2.11. DENTAL PRACTITIONER is a person registered by the Australian Health Practitioner Regulation Agency via the Board to provide dental care.

2.12. A DENTIST is an appropriately qualified dental practitioner, registered by the Board to practise all areas of dentistry.

2.13. DENTISTRY is defined as the evaluation, diagnosis, prevention and/or treatment (nonsurgical, surgical, or reversible and irreversible procedures) of diseases, disorders, irregularities or conditions of the oral cavity, maxillofacial area and/or the adjacent and associated structures and their impact on the human body.

2.14. NEUROTOXINS are substances that interfere with conductivity of motor nerves, thus preventing them from functioning

2.15. OFF-LABEL USE is when a drug is prescribed for an indication, a route of administration, or a patient group that is not included in the approved product information document for that drug. 

3. Policy

3.1. Dentists should be the only dental practitioner able to to administer neurotoxins and dermal fillers. 

3.2. Dentists must comply with any requirements of the Board and their state and territory drugs and poison legislation, including appropriate legal consent requirement. Dentists who use neurotoxins and dermal fillers as part of their practice of dentistry or adjunctive to dentistry will be expected to have completed appropriate education to ensure the safety of the public .

3.3. Before administering neurotoxins and dermal fillers dentists must have knowledge of and skills in:

•patient assessment and consultation for neurotoxins and dermal fillers;

•indications and contraindications for their use;

•safety and risk issues for neurotoxins and dermal filler injectable therapy;

•appropriate preparation and delivery techniques for desired outcomes;

•enhancing and finishing treatments with dermal fillers;

•the pharmacology of neurotoxins and dermal fillers;

•adverse reactions and management of possible complications; and

•the appropriate treatment of temporomandibular disorders with neurotoxins.

3.4. If a dentist does decide to use neurotoxins and dermal fillers off-label then this is a clinical judgement that should be made in consultation with and consent of their patient.

3.5. Before using neurotoxins and dermal fillers dentists must confirm that their professional indemnity policy provides appropriate cover for the treatment.

3.6. Dentists must not delegate treatment involving neurotoxins and dermal fillers. 

Approved by Federal Council

Document Version:
August 2021
Download PDF
Policy Statement 6.30

Adopted by ADA Federal Council, August 27/28, 2015.
Amended by ADA Federal Council, August 23/24, 2018.
Amended by ADA Federal Council. August 19, 2021.